| 1 | bring 100000s in new | | | | | | | 2 | 0.51% |
| 2 | care supervision 30 minutes | | | | | | | 2 | 0.51% |
| 3 | supervision 30 minutes per | | | | | | | 2 | 0.51% |
| 4 | 30 minutes per month | | | | | | | 2 | 0.51% |
| 5 | reviewing charts reports and | | | | | | | 1 | 0.25% |
| 6 | studies conducting team | | | | | | | 1 | 0.25% |
| 7 | diagnostic studies conducting | | | | | | | 1 | 0.25% |
| 8 | treatment plans reviewing | | | | | | | 1 | 0.25% |
| 9 | and treatment plans | | | | | | | 1 | 0.25% |
| 10 | reports and treatment plans | | | | | | | 1 | 0.25% |
| 11 | charts reports and treatment | | | | | | | 1 | 0.25% |
| 12 | wwwdoctoralliancecom 8006085368 sign up | | | | | | | 1 | 0.25% |
| 13 | per month examples | | | | | | | 1 | 0.25% |
| 14 | conducting team conferences | | | | | | | 1 | 0.25% |
| 15 | minutes per month examples | | | | | | | 1 | 0.25% |
| 16 | hospice care supervision 30 | | | | | | | 1 | 0.25% |
| 17 | g0182 hospice care supervision | | | | | | | 1 | 0.25% |
| 18 | health care supervision 30 | | | | | | | 1 | 0.25% |
| 19 | home health care supervision | | | | | | | 1 | 0.25% |
| 20 | conducting team conferences | | | | | | | 1 | 0.25% |
| 21 | conferences discussing drug | | | | | | | 1 | 0.25% |
| 22 | team conferences discussing | | | | | | | 1 | 0.25% |
| 23 | npp time is required | | | | | | | 1 | 0.25% |
| 24 | plan our enterprise partners | | | | | | | 1 | 0.25% |
| 25 | changes to the treatment | | | | | | | 1 | 0.25% |
| 26 | making changes to the | | | | | | | 1 | 0.25% |
| 27 | making changes to | | | | | | | 1 | 0.25% |
| 28 | required making changes | | | | | | | 1 | 0.25% |
| 29 | is required making | | | | | | | 1 | 0.25% |
| 30 | time is required | | | | | | | 1 | 0.25% |
| 31 | or npp time is | | | | | | | 1 | 0.25% |
| 32 | care g0181 home health | | | | | | | 1 | 0.25% |
| 33 | physician or npp time | | | | | | | 1 | 0.25% |
| 34 | coordinating care if | | | | | | | 1 | 0.25% |
| 35 | pharmacist coordinating care | | | | | | | 1 | 0.25% |
| 36 | a pharmacist coordinating | | | | | | | 1 | 0.25% |
| 37 | with a pharmacist | | | | | | | 1 | 0.25% |
| 38 | interactions with a pharmacist | | | | | | | 1 | 0.25% |
| 39 | and interactions with a | | | | | | | 1 | 0.25% |
| 40 | treatment and interactions with | | | | | | | 1 | 0.25% |